Boger RS - Search Results

1

RNA language models predict mutations that improve RNA function.

Shulgina Y, Trinidad MI, Langeberg CJ, Nisonoff H, Chithrananda S, Skopintsev P, Nissley AJ, Patel J, Boger RS, Shi H, Yoon PH, Doherty EE, Pande T, Iyer AM, Doudna JA, Cate JHD. Shulgina Y, et al. Among authors: boger rs. bioRxiv [Preprint]. 2024 Apr 6:2024.04.05.588317. doi: 10.1101/2024.04.05.588317. bioRxiv. 2024. PMID: 38617247 Free PMC article. Preprint.

2

Eukaryotic RNA-guided endonucleases evolved from a unique clade of bacterial enzymes.

Yoon PH, Skopintsev P, Shi H, Chen LX, Adler BA, Al-Shimary M, Craig RJ, Li Z, Amerasekera J, Trinidad M, Nisonoff H, Chen K, Lahiri A, Boger R, Jacobsen S, Banfield JF, Doudna JA. Yoon PH, et al. bioRxiv [Preprint]. 2023 Aug 10:2023.08.09.552727. doi: 10.1101/2023.08.09.552727. bioRxiv. 2023. PMID: 37609353 Free PMC article. Updated. Preprint.

3

RAD in de novo renal transplantation: comparison of three doses on the incidence and severity of acute rejection.

Kahan BD, Kaplan B, Lorber MI, Winkler M, Cambon N, Boger RS. Kahan BD, et al. Among authors: boger rs. Transplantation. 2001 May 27;71(10):1400-6. doi: 10.1097/00007890-200105270-00008. Transplantation. 2001. PMID: 11391226 Clinical Trial.

4

Dose-dependent effects of the renin inhibitor zankiren HCl after a single oral dose in mildly sodium-depleted normotensive subjects.

Ménard J, Boger RS, Moyse DM, Guyene TT, Glassman HN, Kleinert HD. Ménard J, et al. Among authors: boger rs. Circulation. 1995 Jan 15;91(2):330-8. doi: 10.1161/01.cir.91.2.330. Circulation. 1995. PMID: 7805235 Clinical Trial.

5

Simultaneous modeling of the pharmacokinetic and pharmacodynamic properties of enalkiren (Abbott-64662, a renin inhibitor). II: A dose-ranging study in patients with congestive heart failure.

Gupta SK, Granneman GR, Packer M, Boger RS. Gupta SK, et al. Among authors: boger rs. J Cardiovasc Pharmacol. 1993 May;21(5):834-40. doi: 10.1097/00005344-199305000-00022. J Cardiovasc Pharmacol. 1993. PMID: 7685457 Clinical Trial.

6

Simultaneous modeling of the pharmacokinetic and pharmacodynamic properties of enalkiren (Abbott-64662, a new renin inhibitor). I: Single dose study.

Gupta SK, Granneman GR, Boger RS, Hollenberg NK, Luther RR. Gupta SK, et al. Among authors: boger rs. Drug Metab Dispos. 1992 Nov-Dec;20(6):821-5. Drug Metab Dispos. 1992. PMID: 1362933

7

Renin inhibitors in hypertension.

Luther RR, Glassman HN, Boger RS. Luther RR, et al. Among authors: boger rs. Clin Nephrol. 1991 Oct;36(4):181-6. Clin Nephrol. 1991. PMID: 1959244 Review.

8

Immediate blood pressure effects of the renin inhibitor enalkiren and the angiotensin-converting enzyme inhibitor enalaprilat.

Neutel JM, Luther RR, Boger RS, Weber MA. Neutel JM, et al. Among authors: boger rs. Am Heart J. 1991 Oct;122(4 Pt 1):1094-100. doi: 10.1016/0002-8703(91)90477-y. Am Heart J. 1991. PMID: 1656720

9

Effects of renin inhibition in systemic hypertension.

Anderson PW, Do YS, Schambelan M, Horton R, Boger RS, Luther RR, Hsueh WA. Anderson PW, et al. Among authors: boger rs. Am J Cardiol. 1990 Dec 1;66(19):1342-7. doi: 10.1016/0002-9149(90)91165-3. Am J Cardiol. 1990. PMID: 2244565

10

Prolonged duration of blood pressure response to enalkiren, the novel dipeptide renin inhibitor, in essential hypertension.

Boger RS, Glassman HN, Cavanaugh JH, Schmitz PJ, Lamm J, Moyse D, Cohen A, Kleinert HD, Luther RR. Boger RS, et al. Hypertension. 1990 Jun;15(6 Pt 2):835-40. doi: 10.1161/01.hyp.15.6.835. Hypertension. 1990. PMID: 2190927 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

12 results

Search Page